Abstract
Pulmonary fibrosis (PF) in children is a very rare, progressive, and life-threatening condition. There are advances in the treatment of idiopathic PF in adults with the approval of antifibrotics like nintedanib. However, PF treatment in children is still an inconclusive area that needs to be studied further. Here, we present the nintedanib experience in a child with PF.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
